ArticleAME case reports2023
A rare case report: chronic generalized idiopathic pruritus.
Article in AME case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.
- Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review.International journal of dermatology · 2026Pooled it
- Clinical application of ozone hydrotherapy combined with scalp complex acid treatment for moderate to severe scalp seborrheic dermatitis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Generalized chronic pruritus (CP) can be associated with seborrheic dermatitis and psoriasis but often can present without any noticeable diagnosis or obvious skin lesion. When not related to a clear diagnosis, CP can be characterized as idiopathic pruritus. CP is both a diagnostically and therapeutically challenging presentation due to the variety of systemic, dermatological, neurological, and psychogenic diseases that must be ruled out before diagnosing idiopathic pruritus. This presentation is often overlooked but can lead to a greatly diminished quality of life for patients who present with idiopathic generalized pruritus. The course of treatment will vary between providers and specialties, however, most dermatologists will attempt control with antihistamines, topical steroids, or oral steroids. The use of gabapentinoids for the treatment of CP is understudied. Gabapentin was initially developed as an antiepileptic that has since been approved to treat neuropathic pain and has a common off-label use in dermatology and can be used to effectively treat CP. Case Description: Here we present a case of a 56-year-old Caucasian male who presented to the outpatient dermatology clinic with new-onset, diffuse, and intense pruritic symptoms that gradually progressed over a period of seven weeks. This case study details a patient with Idiopathic generalized pruritus previously uncontrolled that was well-controlled with the use of gabapentin after trials of other common treatments failed. Conclusions: The understudied off-label use of gabapentin in the case of generalized chronic idiopathic pruritus should be explored and later implemented as a mainstay for patients suffering from uncontrolled CP as it was shown to completely eliminate pruritic symptoms and improve the quality of life for this patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.